PAXMAN AB This week, important abstracts highlighting the use of cryotherapy in the prevention and management of adverse effects of chemotherapy treatment were presented by key international experts at the eminent international conference on supportive cancer care, the MASCC/AFSOS/ISOO 2024 Annual Meeting in
Today, the
The study concludes that the use of limb cryocompression:
- is safe and well-tolerated in patients receiving taxane-based chemotherapy
- can be safely administered with scalp cooling therapy
- shows promising data in preventing taxane-based CIPN with no significant change in sensory scores reported
- facilitates the effective dose delivery of taxane-based chemotherapy
A multi-centered three-arm randomized controlled study is ongoing in
Richard Paxman OBE, CEO of Paxman Scalp Cooling commented,” We are very proud to work with so many inspiring thought leaders from around the world who have such a shared passion to create collective impact. This year it is impressive to see so many presentations featuring cryotherapy for the prevention and management of adverse effects of chemotherapy treatment on the agenda at the MASCC/AFSOS/ISOO Annual Meeting. My colleagues and I were delighted to learn more, and ultimately together help patients access treatments that we know can have a real impact on their lives during and after cancer treatment.”
Fellow authors and colleagues, Dr
About CIPN
CIPN is a severe dose-limiting toxicity of paclitaxel and docetaxel, which are both widely used drugs for the treatment of common cancers including breast, ovarian, endometrial, lung, and gastric cancers[i]. CIPN is extremely prevalent; rates of Grade 2 or higher sensory neuropathy have been reported at 27% in patients with breast cancer (BC) after 12 cycles of weekly paclitaxel and at 20-21% in patients with endometrial or ovarian cancer who received 6 cycles of 3-weekly paclitaxel and carboplatin.([ii], [iii], [iv]) CIPN has a profound impact on the quality of life for over 1.4 million cancer patients annually, often limiting daily functioning and motor activities, and can persist for years after treatment [v], [vi]. CIPN increases healthcare costs by approximately
Patients can experience numbness, tingling, altered touch sensation, gait and balance disturbances, burning pain, thermal allodynia or hyperalgesia, impaired vibration sense, extreme temperature sensitivity, paraesthesia and/or dysesthesia. A patient experiencing CIPN symptoms may have difficulty performing daily functions such as walking, dressing themselves, writing, typing, using mobile phones, using utensils and other activities related to the hands and feet. 68.1% of patients can experience CIPN symptoms in the first month after the completion of chemotherapy.
At present, dose modification is the most successful approach to prevent worsening CIPN; however, there is potential for lower chemotherapy efficacy, which could result in poorer survival. There has been considerable emerging interest in non-pharmacological approaches such as cryotherapy and compression therapy. Since 2019, Paxman has worked in partnership with a
For more information about Paxman’s ongoing clinical trials please visit:
https://scalpcoolingstudies.com/ongoing-clinical-trials/
© Modular Finance, source
